Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study
Top Cited Papers
- 27 June 2022
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 9 (8) , e554-e562
Abstract
No abstract availableKeywords
Funding Information
- Sidaction
- Merck
- ANRS
- Ile-de-France Regional Council
- Gilead Sciences
- Janssen Pharmaceutica
This publication has 21 references indexed in Scilit:
- Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipelineThe Lancet HIV, 2019
- Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration studyThe Lancet HIV, 2019
- Cohort profile: l’Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, CanadaBMJ Open, 2019
- First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabineJournal of Antimicrobial Chemotherapy, 2019
- Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxisAIDS, 2018
- Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort studyThe Lancet HIV, 2017
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 InfectionNew England Journal of Medicine, 2015
- Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyThe Lancet Infectious Diseases, 2014
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010